Pharmaceuticals company Cipla announced Q1FY26 results Income from Operations: Rs 6,957 crore compared to Rs 6,694 crore during Q1FY25, change 3.9%. EBITDA: Rs 1,778 crore compared to Rs 1,716 crore during Q1FY25, change 3.6%. EBITDA Margin: 25.6% for Q1FY26. PAT: Rs 1,298 crore compared to Rs 1,178 crore during Q1FY25, change 10.2%. Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of $ 226 Mn. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered a substantial revenue growth of 20% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front." Result PDF